Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Medullary breast carcinoma, a triple-negative breast cancer subtype associated with BCLG overexpression and BRCAness

ABSTRACT: Medullary breast carcinoma, a triple-negative breast cancer subtype associated with BCLG overexpression and BRCAness

PROVIDER: PRJNA470708 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Medullary breast carcinoma, a triple-negative breast cancer subtype associated with BRCAness.

Project description:Medullary breast carcinoma, a triple-negative breast cancer subtype associated with BRCAness.

| PRJNA470674 | ENA

Medullary breast carcinoma, a triple-negative breast cancer subtype associated with BCLG overexpression.

Project description:Medullary breast carcinoma, a triple-negative breast cancer subtype associated with BCLG overexpression.

| PRJNA466799 | ENA

Medullary breast carcinoma, a triple-negative breast cancer subtype associated with BCLG overexpression.

Project description:Gene expression was compared between medullary breast carcinoma (MBC) and non medullary basal-like breast carcinoma (non-MBC BLC).

2018-06-20 | GSE114168 | GEO

Medullary breast carcinoma, a triple-negative breast cancer subtype associated with BRCAness.

Project description:Genome profiling was compared between medullary breast carcinoma (MBC) and non medullary basal-like breast carcinoma (non-MBC BLC).

2018-06-20 | GSE114183 | GEO

18 PDX of triple-negative breast cancer genotyped with SNP6 Affymetrix arrays

Project description:To characterize Homologous recombination deficiency (BRCAness) in triple-negative breast cancer PDX models genomic signature was utilized. After normalization using Genotyping Console we obtained absolute copy number profiles using the GAP software (Popova et al, Genome Biol, 2009). The number of Large-scale State Transitions (LSTs) was used to annotate PDX as BRCAness or not (Popova et al, Cancer Res 2012).

2020-01-01 | E-MTAB-8654 | biostudies-arrayexpress

22 PDX of triple-negative breast cancer genotyped with Affymetrix Cytoscan HD

Project description:To characterize Homologous recombination deficiency (BRCAness) in triple-negative breast cancer PDX models genomic signature was utilized. After normalization using ChAS we obtained absolute copy number profiles using the GAP software (Popova et al, Genome Biol, 2009). The number of Large-scale State Transitions (LSTs) was used to annotate PDX as BRCAness or not (Popova et al, Cancer Res 2012).

2020-01-01 | E-MTAB-8653 | biostudies-arrayexpress

Expression data for Vanderbilt triple-negative breast cancer subtype classification

Project description:This study developed a triple-negative breast cancer (TNBC) surrogate subtype classification that represents TNBC subtypes based on the Vanderbilt subtype classification The web-based subtyping tool TNBCtype was used to classify the TNBC cohort into Vanderbilt subtypes

2023-03-04 | GSE226289 | GEO

Expression data for Vanderbilt triple-negative breast cancer subtype classification

Project description:Expression data for Vanderbilt triple-negative breast cancer subtype classification

| PRJNA939561 | ENA

Differential analysis of nucleolar proteomics in triple negative breast cancer

Project description:Breast cancer is one of the most common cancers in women. Of the different subtypes of breast cancer, the triple negative breast cancer subtype of breast cancer is the most aggressive. A proteomic screen of nucleolar content across breast cancer subtypes found that triple negative breast cancer cell lines have a distinct nucleolar proteome signature in comparison to non-TNBC breast cancer cell lines.

2021-03-05 | PXD021201 | Pride

Phenotypic and Molecular Characterization of the Claudin-low Intrinsic Subtype of Breast Cancer

Project description:In breast cancer, gene expression analyses have defined five tumor subtypes, each of which has unique biologic and prognostic features. Here, we characterize the recently identified claudin-low tumor subtype as showing low to absent expression of luminal differentiation markers, high enrichment for epithelial-to-mesenchymal transition markers, immune response genes, and cancer stem cell–like features. Clinically, most claudin-low tumors are poorprognosis estrogen receptor–negative, progesterone receptor–negative, and human epidermal growth factor receptor 2–negative (triple-negative) invasive ductal carcinomas with a high frequency of metaplastic and medullary differentiation. They also have a response rate to standard preoperative chemotherapy that is intermediate between that of basal-like and luminal tumors. Moreover, we show that a group of highly used breast cancer cell lines, and several genetically engineered mouse models, express the claudin-low phenotype. Finally, we confirm that a prognostically relevant differentiation hierarchy exists across all breast cancers in which the claudin-low subtype most closely resembles the mammary epithelial stem cell. These results should help to improve our understanding of the biologic heterogeneity of breast cancer and provide tools for the further evaluation of the unique biology of claudin-low tumors and cell lines.

2010-06-15 | GSE18229 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data